Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Treatment for newly diagnosed glioblastomas currently involves surgical resection followed by
Temozolomide chemotherapy with concomitant radiotherapy, and then 6 cycles of Temozolomide in
adjuvant. According to many studies, only those patients not expressing the enzyme repair
MGMT benefit from the adjunction of Temozolomide. Therefore, many patients receive
unnecessary treatment. The aim of this project is to compare different techniques for
analysis of MGMT in order to choose the approach with the best cost/utility ratio, which will
allow the selection of patients likely to respond to TMZ chemotherapy during the first course
of GBM treatment.